Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA

James M. Rae, Meredith M. Regan, Jacklyn N. Thibert, Christina Gersch, Dafydd Thomas, Brian Leyland-Jones, Giuseppe Viale, Lajos Pusztai, Daniel F. Hayes, Todd Skaar, Catherine Van Poznak

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Formalin-fixed, paraffin-embedded tumors (FFPETs) are a valuable source of DNA for genotype association studies and are often the only germline DNA resource from cancer clinical trials. The anti-estrogen tamoxifen is metabolized into endoxifen by CYP2D6, leading to the hypothesis that patients with certain CYP2D6 genotypes may not receive benefit because of their inability to activate the drug. Studies testing this hypothesis using FFPETs have provided conflicting results. It has been postulated that CYP2D6 genotype determined using FFPET may not be accurate because of somatic tumor alterations. In this study, we determined the concordance between CYP2D6 genotypes generated using 3 tissue sources (FFPETs; formalin-fixed, paraffinembedded unaffected lymph nodes [FFPELNs]; and whole blood cells [WBCs]) from 122 breast cancer patients. Compared with WBCs, FFPET and FFPELN genotypes were highly concordant (>94%), as were the predicted CYP2D6 metabolic phenotypes (>97%). We conclude that CYP2D6 genotypes obtained from FFPETs accurately represent the patient's CYP2D6 metabolic phenotype.

Original languageEnglish (US)
Pages (from-to)1332-1334
Number of pages3
JournalJournal of the National Cancer Institute
Volume105
Issue number17
DOIs
StatePublished - Sep 4 2013
Externally publishedYes

Fingerprint

Cytochrome P-450 CYP2D6
Formaldehyde
Genotype
Paraffin
DNA
Neoplasms
Blood Cells
Lymph Nodes
Phenotype
Tamoxifen
Estrogens
Clinical Trials
Breast Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Rae, J. M., Regan, M. M., Thibert, J. N., Gersch, C., Thomas, D., Leyland-Jones, B., ... Van Poznak, C. (2013). Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. Journal of the National Cancer Institute, 105(17), 1332-1334. https://doi.org/10.1093/jnci/djt204

Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. / Rae, James M.; Regan, Meredith M.; Thibert, Jacklyn N.; Gersch, Christina; Thomas, Dafydd; Leyland-Jones, Brian; Viale, Giuseppe; Pusztai, Lajos; Hayes, Daniel F.; Skaar, Todd; Van Poznak, Catherine.

In: Journal of the National Cancer Institute, Vol. 105, No. 17, 04.09.2013, p. 1332-1334.

Research output: Contribution to journalArticle

Rae, JM, Regan, MM, Thibert, JN, Gersch, C, Thomas, D, Leyland-Jones, B, Viale, G, Pusztai, L, Hayes, DF, Skaar, T & Van Poznak, C 2013, 'Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA', Journal of the National Cancer Institute, vol. 105, no. 17, pp. 1332-1334. https://doi.org/10.1093/jnci/djt204
Rae JM, Regan MM, Thibert JN, Gersch C, Thomas D, Leyland-Jones B et al. Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. Journal of the National Cancer Institute. 2013 Sep 4;105(17):1332-1334. https://doi.org/10.1093/jnci/djt204
Rae, James M. ; Regan, Meredith M. ; Thibert, Jacklyn N. ; Gersch, Christina ; Thomas, Dafydd ; Leyland-Jones, Brian ; Viale, Giuseppe ; Pusztai, Lajos ; Hayes, Daniel F. ; Skaar, Todd ; Van Poznak, Catherine. / Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. In: Journal of the National Cancer Institute. 2013 ; Vol. 105, No. 17. pp. 1332-1334.
@article{70b2fd9ad76b4f119a8c9d7ff4634ea2,
title = "Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA",
abstract = "Formalin-fixed, paraffin-embedded tumors (FFPETs) are a valuable source of DNA for genotype association studies and are often the only germline DNA resource from cancer clinical trials. The anti-estrogen tamoxifen is metabolized into endoxifen by CYP2D6, leading to the hypothesis that patients with certain CYP2D6 genotypes may not receive benefit because of their inability to activate the drug. Studies testing this hypothesis using FFPETs have provided conflicting results. It has been postulated that CYP2D6 genotype determined using FFPET may not be accurate because of somatic tumor alterations. In this study, we determined the concordance between CYP2D6 genotypes generated using 3 tissue sources (FFPETs; formalin-fixed, paraffinembedded unaffected lymph nodes [FFPELNs]; and whole blood cells [WBCs]) from 122 breast cancer patients. Compared with WBCs, FFPET and FFPELN genotypes were highly concordant (>94{\%}), as were the predicted CYP2D6 metabolic phenotypes (>97{\%}). We conclude that CYP2D6 genotypes obtained from FFPETs accurately represent the patient's CYP2D6 metabolic phenotype.",
author = "Rae, {James M.} and Regan, {Meredith M.} and Thibert, {Jacklyn N.} and Christina Gersch and Dafydd Thomas and Brian Leyland-Jones and Giuseppe Viale and Lajos Pusztai and Hayes, {Daniel F.} and Todd Skaar and {Van Poznak}, Catherine",
year = "2013",
month = "9",
day = "4",
doi = "10.1093/jnci/djt204",
language = "English (US)",
volume = "105",
pages = "1332--1334",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "17",

}

TY - JOUR

T1 - Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA

AU - Rae, James M.

AU - Regan, Meredith M.

AU - Thibert, Jacklyn N.

AU - Gersch, Christina

AU - Thomas, Dafydd

AU - Leyland-Jones, Brian

AU - Viale, Giuseppe

AU - Pusztai, Lajos

AU - Hayes, Daniel F.

AU - Skaar, Todd

AU - Van Poznak, Catherine

PY - 2013/9/4

Y1 - 2013/9/4

N2 - Formalin-fixed, paraffin-embedded tumors (FFPETs) are a valuable source of DNA for genotype association studies and are often the only germline DNA resource from cancer clinical trials. The anti-estrogen tamoxifen is metabolized into endoxifen by CYP2D6, leading to the hypothesis that patients with certain CYP2D6 genotypes may not receive benefit because of their inability to activate the drug. Studies testing this hypothesis using FFPETs have provided conflicting results. It has been postulated that CYP2D6 genotype determined using FFPET may not be accurate because of somatic tumor alterations. In this study, we determined the concordance between CYP2D6 genotypes generated using 3 tissue sources (FFPETs; formalin-fixed, paraffinembedded unaffected lymph nodes [FFPELNs]; and whole blood cells [WBCs]) from 122 breast cancer patients. Compared with WBCs, FFPET and FFPELN genotypes were highly concordant (>94%), as were the predicted CYP2D6 metabolic phenotypes (>97%). We conclude that CYP2D6 genotypes obtained from FFPETs accurately represent the patient's CYP2D6 metabolic phenotype.

AB - Formalin-fixed, paraffin-embedded tumors (FFPETs) are a valuable source of DNA for genotype association studies and are often the only germline DNA resource from cancer clinical trials. The anti-estrogen tamoxifen is metabolized into endoxifen by CYP2D6, leading to the hypothesis that patients with certain CYP2D6 genotypes may not receive benefit because of their inability to activate the drug. Studies testing this hypothesis using FFPETs have provided conflicting results. It has been postulated that CYP2D6 genotype determined using FFPET may not be accurate because of somatic tumor alterations. In this study, we determined the concordance between CYP2D6 genotypes generated using 3 tissue sources (FFPETs; formalin-fixed, paraffinembedded unaffected lymph nodes [FFPELNs]; and whole blood cells [WBCs]) from 122 breast cancer patients. Compared with WBCs, FFPET and FFPELN genotypes were highly concordant (>94%), as were the predicted CYP2D6 metabolic phenotypes (>97%). We conclude that CYP2D6 genotypes obtained from FFPETs accurately represent the patient's CYP2D6 metabolic phenotype.

UR - http://www.scopus.com/inward/record.url?scp=84884494450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884494450&partnerID=8YFLogxK

U2 - 10.1093/jnci/djt204

DO - 10.1093/jnci/djt204

M3 - Article

C2 - 23958736

AN - SCOPUS:84884494450

VL - 105

SP - 1332

EP - 1334

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 17

ER -